Daily Activity and Clinical Outcome Measurement of Arthrosamid® Administration in Symptomatic Knee Osteoarthritis.

Inclusion criteria

• Subjects > 18 years of age at the time of injection
• Advanced osteoarthritis, involving one or multiple of the following phenotypes: tricompartmental osteoarthritis, isolated or severe patella-femoral osteoarthritis, and/or a Kellgren and Lawrence grade II or III classification:

• Patellofemoral osteoarthritis referring to symptoms, including pain, that are principally of patellofemoral origin (Patellar syndrome).
• Radiological Kellgren and Lawrence grade II to III from a standing knee radiograph taken less than 6 months previously.
• Subjects with a normal BMI ≥ 18.5 kg/m² and < 30 kg/m²
• Symptomatic osteoarthritis diagnosed via radiographic assessment and according to the clinical and radiological criteria of the American College of Rheumatology
• Fully ambulatory patient for functional evaluation.
• Able to understand and follow the instructions of the study.
• Having signed a written informed consent

Exclusion criteria

• Meeting one of the following contraindications as stated in the instructions for use (IFU) of Arthrosamid®:

• If an active skin disease or infection is present at or near the injection site
• If the joint is infected or severely inflamed
• If a degradable intra-articular injectable such as hyaluronic acid is present, it must be expected to be absorbed according to the manufacturer's information for the specific product, before injection with Arthrosamid®
• Other medical conditions contributing to the rehabilitation process of the injection according to the surgeon
• Important medical conditions such as, Parkinson's Disease, dementia, multiple sclerosis and cerebral vascular accident, which can disturb the patient's rehabilitation after injection according to the surgeon
• Patient is participating in another clinical trial or has participated in a clinical trial in the last three months
• Patients who did not met all the inclusion criteria